Ascendis Pharma A (ASND) Common Equity (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Common Equity data on file, last reported at $571.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 386.14% year-over-year to $571.3 million; the trailing twelve-month figure through Mar 2026 stood at $571.3 million (up 386.14% YoY), and the FY2025 full-year result was -$189.5 million, down 107.32% from the prior year.
• Common Equity advanced to $571.3 million in Q1 2026, from -$189.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.6 billion in Q4 2024 to a low of -$345.8 million in Q2 2024.
• A 5-year average of $220.7 million and a median of -$79.9 million in 2023 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 1730.95% in 2024, while the deepest fall reached 589.79% in 2024.
• Tracing ASND's Common Equity over 5 years: stood at $268.7 million in 2022, then sank by 158.34% to -$156.8 million in 2023, then surged by 1730.95% to $2.6 billion in 2024, then tumbled by 107.41% to -$189.5 million in 2025, then soared by 401.42% to $571.3 million in 2026.
• Business Quant data shows ASND's Common Equity at $571.3 million in Q1 2026, -$189.5 million in Q4 2025, and -$203.5 million in Q3 2025.